These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30512650)

  • 21. HMG CoA reductase inhibitors (statins) for dialysis patients.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Primary prevention of cardiovascular diseases with statins in women].
    Alici G; Karpuz V; Karpuz H
    Turk Kardiyol Dern Ars; 2009 Jun; 37(4):273-80. PubMed ID: 19717964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins in primary prevention: impact on mortality. A meta-analysis study.
    Nunes JP
    Minerva Cardioangiol; 2017 Oct; 65(5):531-538. PubMed ID: 28249380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
    Saib A; Sabbah L; Perdrix L; Blanchard D; Danchin N; Puymirat E
    Arch Cardiovasc Dis; 2013 Oct; 106(10):511-6. PubMed ID: 24080324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Statins in primary prevention - a must for the general practitioner?].
    Zoller M
    Praxis (Bern 1994); 2011 Jul; 100(14):859-60. PubMed ID: 21732299
    [No Abstract]   [Full Text] [Related]  

  • 26. Starting primary prevention earlier with statins.
    Robinson JG
    Am J Cardiol; 2014 Nov; 114(9):1437-42. PubMed ID: 25205631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses.
    Huded C; Prasad V
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):379-86. PubMed ID: 26141958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice.
    Kazi DS; Penko JM; Bibbins-Domingo K
    Med Clin North Am; 2017 Jul; 101(4):689-699. PubMed ID: 28577620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesterol management and the reduction of cardiovascular risk.
    Nixon JV
    Prev Cardiol; 2004; 7(1):34-9; quiz 40-1. PubMed ID: 15010626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.
    Odden MC; Pletcher MJ; Coxson PG; Thekkethala D; Guzman D; Heller D; Goldman L; Bibbins-Domingo K
    Ann Intern Med; 2015 Apr; 162(8):533-41. PubMed ID: 25894023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.
    de Vries FM; Kolthof J; Postma MJ; Denig P; Hak E
    PLoS One; 2014; 9(11):e111247. PubMed ID: 25372483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.
    Ray KK; Seshasai SR; Erqou S; Sever P; Jukema JW; Ford I; Sattar N
    Arch Intern Med; 2010 Jun; 170(12):1024-31. PubMed ID: 20585067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Statin therapy--for whom?].
    Kahri J; Syvänne M
    Duodecim; 2012; 128(8):811-8. PubMed ID: 22616372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis.
    Chen YH; Feng B; Chen ZW
    Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):116-20. PubMed ID: 22187291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks.
    Minder CM; Blumenthal RS; Blaha MJ
    Curr Opin Cardiol; 2013 Sep; 28(5):554-60. PubMed ID: 23928920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS].
    Lavie G; Cohen S
    Harefuah; 2015 Jun; 154(6):382-6, 404. PubMed ID: 26281083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality.
    Rossignol M; Labrecque M; Cauchon M; Breton MC; Poirier P
    Fam Pract; 2018 Jul; 35(4):376-382. PubMed ID: 29267889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
    Hou W; Lv J; Perkovic V; Yang L; Zhao N; Jardine MJ; Cass A; Zhang H; Wang H
    Eur Heart J; 2013 Jun; 34(24):1807-17. PubMed ID: 23470492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data.
    Mansi IA
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):407-418. PubMed ID: 27677504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins.
    Andrade C
    Bipolar Disord; 2013 Dec; 15(8):813-23. PubMed ID: 24119211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.